Qms Medical Allied Services Limited · NSE:QMSMEDI
Qms Medical Allied Services — H1 FY26 Earnings Presentation
31 slides from Qms Medical Allied Services's earnings presentation, Nov 17, 2025
Slide 1: Exchange filing cover letter under Regulation 30
To, National Stock Exchange of India Ltd. Plaza, C 1, Block G, Bandra - Kurla Complex, Bandra (E), Mumbai – 400 051, Maharashtra, India. Company Symbol: QMSMEDI ISIN: INE0FMW01018 Ref: QMS MEDICAL ALLIED SERVICES LIMITED Sub: Announcement under Regulation 30 of Securities and Exchange Board of India
Slide 2: QMS Medical Allied Services Ltd Investor Presentation Q2 & H1FY26
QMS Medical Allied Services Ltd Trusted partner for Medical Services & Patient Journey Programs Investor Presentation – Q2 & H1FY26
Slide 3: Disclaimer
Disclaimer This presentation and the accompanying slides (the “Presentation”), has been prepared by QMS Medical Allied Services Ltd (the “Company”), solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall no
Slide 4: Table of Contents
Table of Contents 1 2 3 Q2 & H1FY26 Company Our Highlights Overview Offerings 4 5 Opportunity Annual Landscape Financials 3
Slide 5: Q2 & H1FY26 Highlights
Q2 & H1FY26 Highlights
Slide 6: Management Commentary
Management Commentary It gives me great pleasure to present the Q2 and H1 FY26 performance highlights of QMS Medical Allied Services Ltd. We delivered a steady performance in Q2 FY26 with revenues of ₹44.7 crore, growing 20% YoY, and an EBITDA of ₹6.9 crore at a 15.5% margin. PAT stood at ₹3.6 crore
Slide 7: Consolidated Financial Performance - Q2 & H1FY26
Consolidated Financial Performance - Q2 & H1FY26 Revenue from Operations (Rs Cr) EBITDA (Rs Cr) & EBITDA Margin (%) PAT (Rs Cr) & PAT Margin (%) Segment Revenue Mix (%) 20% 19.5% 15.5% 11.4% 8.0% H1FY26 44.7 37.2 Quarterly 24% 7.2 6.9 4.2 3.6 76% Q2FY25 Q2FY26 Q2FY25 Q2FY26 Q2FY25 Q2FY26 H1FY25
Slide 8: Consolidated Profit & Loss Statement – Q2 & H1FY26
Consolidated Profit & Loss Statement – Q2 & H1FY26 Particulars (Rs Cr) Q2FY26 Q2FY25 Y-o-Y % Q1FY26 Q-o-Q % H1FY26 H1FY25 Y-o-Y % Net Revenue from Operations 44.7 37.2 20% 46.5 -4% 91.2 67.6 35% COGS 25.6 19.2 25.9 51.5 36.4 Gross Profit 19.1 18.0 6% 20.6 -7% 39.7 31.1 27% Gross Profit Margin (%) 42
Slide 9: Company Overview
Company Overview
Slide 10: QMS – A Key Player in Integrated Healthcare Ecosystem
QMS – A Key Player in Integrated Healthcare Ecosystem Founded in 1994, QMS has grown from a pharma marketing solutions provider into a trusted healthcare partner. QMS MAS is a leading distributor and marketer of a diverse range of medical products, and has also expanded into high-growth services lik
Slide 11: Unique Value Proposition
Unique Value Proposition 30 years of Industry Experience Promoters & Management Team Holistic Solutions Provider Strong Capabilities / Entry Barrier ✓ Proven expertise in healthcare ✓ Experienced leadership with ✓ Offers integrated smart devices ✓ Pan India network spanning 100+ ecosystem strong pha
Slide 12: Our Remarkable Journey over 30 Years
Our Remarkable Journey over 30 Years 1994 – 2005 2006-2015 2016-2020 2021-2025 • Formation of Queens • Exclusive partnership with Heine • Formation of QMS MAS (Pvt. Ltd) • Launched the Patient Service Marketing Services as a for Diagnostic Equipment in 2008 in 2017 Programs (PSP) services in 2021 so
Slide 13: Distinguished Board of Directors
Distinguished Board of Directors CA Prajwal Poojari Independent Director Mahesh Makhija Dr. Guddi Makhija Dr. D N. Pathak • Chartered Accountant with over 15 Founder, Chairman and Managing Director Medical Training & Administration Principal Advisor years of professional experience. • Founded the co
Slide 14: Experienced Management Team
Experienced Management Team Charles James Kaushik Guha Thakurta Abhishek Tiwari Head of E-Commerce General Manager, B2B Sales & Marketing General Manager, B2B Sales & Marketing • Joined QMS MAS in 1999, currently heads the E- • Served as the General Manager of QMS MAS since 2014. • Joined QMS MAS in
Slide 15: Our Offerings – Products & Services
Our Offerings – Products & Services
Slide 16: 1. Product – Extracting Value in a Competitive Space
1. Product – Extracting Value in a Competitive Space… With a legacy of ~30 years in the industry, we ensure reliable Q-Devices - Launched in 2023, offering a range of Medical/Wellness Devices distribution, foster strong partnerships, and leverage nationwide reach to make healthcare more accessible ✓
Slide 17: Marketed and Distributed through Offline and Online Modes
…Marketed and Distributed through Offline and Online Modes Pharma Cos. and Hospitals Point of Care E-commerce ✓ Collaboration with 50+ (including the Top 10) ✓ Provides strips/consumables during doctor clinic ✓ QMSMEDS: Owned and Developed in-house, for a leading Pharma Companies in India camps, ena
Slide 18: 2. B2B Camps – Pharma Driven Health Engagements
2. B2B Camps – Pharma Driven Health Engagements Pharma backed B2B Camps ✓ QMS acts as the backend service provider, enabling pharma companies to conduct structured, short- duration health camps at doctors’ clinics ✓ Pharma companies, through their medical representatives, engage doctors and mobilize
Slide 19: 3. Patient Support Programs – Enhancing Patient Outcomes
3. Patient Support Programs – Enhancing Patient Outcomes… What is Patient Support Programs (PSP)? Scope for QMS PSP provides customized Patient Support and Outreach ✓ QMS manages end-to-end patient management, including reminders, consultations, and Programs designed to improve treatment outcomes fo
Slide 20: Through Our Proprietary Integrated Technology Platform
…through Our Proprietary Integrated Technology Platform Key Advantages QMSMAS Patient Service Ecosystem: Scalable Healthcare Innovation Emphasizes the strengths and value propositions Focus on patient care, scalability (via AWS), and innovative healthcare solutions of the QMSMAS Ecosystem Tele Inter
Slide 21: Case Study: HumRahi - Flagship PSP Partnership with Lupin
Case Study: HumRahi - Flagship PSP Partnership with Lupin Exclusive Patient Support Program by Lupin, managed by QMS Scale & Reach • 10,000+ patients empowered so far Covers multiple chronic/specialty conditions: • Available in 15+ languages, Diabetes, Hypertension, Cardiology, Respiratory, Ophthalm
Slide 22: 4. Educamedics – Bridging Education and Healthcare
4. Educamedics – Bridging Education and Healthcare Specialized Medical Education ✓ Provides specialized education for healthcare professionals to stay updated with the latest medical knowledge. ✓ Delivers tailored and reliable learning through online courses, webinars, conferences, and recorded lect
Slide 23: Opportunity Ecosystem
Opportunity Ecosystem
Slide 24: Market Opportunity Landscape
Market Opportunity Landscape The Total Indian Pharma Market is estimated to reach a value of INR 239,600 Cr. in 2024 Key Drivers (source: IQVIA report), of which Retail Sector may account for an estimated Rs. 177,300 Cr • Regulatory Shift: Stricter limits on direct promotions boost PSP growth and pa
Slide 25: Roadmap to Scalable Growth
Roadmap to Scalable Growth Q-Devices Scale-Up eGrameen Portal Access Driving sustainable growth through Exclusive healthcare vendor – unlocking diagnostics, home-care solutions, and PSP underserved rural and semi-urban integration markets for Q-Devices & partner products Large-Scale Patient Support
Slide 26: Annual Financials
Annual Financials
Slide 27: Key Financial Metrics
Key Financial Metrics Revenue from Operations (Rs Cr) EBITDA (Rs Cr) & EBITDA Margin (%) PAT (Rs Cr) & PAT Margin (%) Earnings Per Share (Rs) 156 16.3% 15.0% 8.8% 120 7.4% 6.8 104 10.9% 6.1% 25.4 5.0 13.7 18.3 3.9 9.0 11.3 6.4 FY23 FY24 FY25 FY23 FY24 FY25 FY23 FY24 FY25 FY23 FY24 FY25 ROE & ROCE (%
Slide 28: Consolidated Profit & Loss Statement
Consolidated Profit & Loss Statement Particulars (Rs Cr) FY23 FY24 FY25 CAGR Net Revenue from Operations 104.0 122.1 156.0 22% COGS 77.9 79.9 81.6 Gross Profit 26.2 42.2 74.4 Gross Profit Margin (%) 25.1% 34.6% 47.7% Employee Expenses 3.7 5.5 9.6 Other expenses 11.1 18.4 39.4 EBITDA 11.3 18.3 25.4 5
Slide 29: Consolidated Balance Sheet
Consolidated Balance Sheet Liabilities (Rs Cr) Mar-23 Mar-24 Mar-25 Sept-25 Assets (Rs Cr) Mar-23 Mar-24 Mar-25 Sept-25 Share Capital 17.9 17.9 17.9 19.3 Property, Plant & Equipment and 26.5 25.6 26.8 26.1 Intangible Assets Reserves & Surplus 52.6 60.7 71.9 85.9 Capital Works-in-Progress 0.0 0.0 0.0
Slide 30: Consolidated Cash Flow Statement
Consolidated Cash Flow Statement Particulars (Rs Cr) FY23 FY24 FY25 H1FY26 Net Profit Before Tax and Extraordinary items 8.7 12.2 18.7 9.3 Adjustments for: Non-Cash Items / Other Investment or Financial Items 0.7 3.3 3.5 2.2 Operating Profit Before Working Capital Changes 9.4 15.5 22.2 11.5 Changes
Slide 31: Thank You
Thank You QMS Medical Allied Services Ltd Stellar IR Advisors Ltd Tanay Surkund Ankit Jain tanaysurkund@qmsmas.com ankit@stellar-ir.com 022 6288 1111 +91 22 62398024 1A-B/2A-B, Navkala Bharti Building, Road No.3, Santacruz East, Mumbai 400055 A-405, Kanakia Wall Street, Andheri (East), Mumbai 400 09
QMS Medical Allied Services — H1 FY26 Earnings Presentation on 6ix